Bildkälla: Stockfoto

Vicore Pharma: IPF KOL Seminar and External Covid-19 News - Redeye

Redeye maintains our positive take on C21 in IPF following last weeks Key Opinion Leader Seminar hosted by Vicore Pharma. Furthermore, we comment on the external Covid-19 news that Merck’s antiviral candidate Molnupiravir showed promising data in a phase III study in mild to moderate Covid-19.

Redeye maintains our positive take on C21 in IPF following last weeks Key Opinion Leader Seminar hosted by Vicore Pharma. Furthermore, we comment on the external Covid-19 news that Merck’s antiviral candidate Molnupiravir showed promising data in a phase III study in mild to moderate Covid-19.
Börsvärldens nyhetsbrev
ANNONSER